^18F-FDG PET/CT SUVmax值对弥漫大B细胞淋巴瘤患者R-CHOP治疗生存预后分析  

Prognostic value of F-FDG PET/CT SUVmax before R-CHOP treatment for diffuse large B cell lymphoma:an analysis of 76 cases

作　　者：雷成明[1] 王丽丹 李文波[1] 黄颖[1] 邓熙 牛梦达 彭志平[1] LEI Chengming;WANG Lidan;LI Wenbo;HUANG Ying;DENG Xi;NIU Mengda;PENG Zhiping(Department of Nuclear Medicine,the First Affiliated Hospital of Chongqing Medical University,Chongqing,400016;Department of Radiological Medicine,College of Basic Medical Sciences,Chongqing Medical University,Chongqing,400016,China)

机构地区：[1]重庆医科大学附属第一医院核医学科,重庆400016 [2]重庆医科大学基础医学院放射医学教研室,重庆400016

出　　处：《第三军医大学学报》2020年第17期1693-1698,共6页Journal of Third Military Medical University

摘　　要：目的探讨R-CHOP治疗前^18F-脱氧葡萄糖(^18F-fluorodeoxy glucose,^18F-FDG)正电子发射计算机断层扫描(positron emission tomography/computed tomograph,PET/CT)检查最大标准摄取值(maximum standard uptake value,SUVmax)对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者生存预测价值。方法收集重庆医科大学附属第一医院2015-2019年在R-CHOP治疗前进行^18F-FDG PET/CT检查的76例DLBCL患者的临床资料,应用R-Studio软件对DLBCL患者的年龄、性别、^18F-FDG PET/CT显像的SUVmax值以及免疫学标志物和免疫分型等进行单因素及多因素预后分析;根据SUVmax值将76例DLBCL患者分为SUVmax≤10组和SUVmax>10组,采用χ^2检验比较两组间年龄、性别、临床分期、B症状、乳酸脱氢酶(lactic dehydrogenase,LDH)、IPI评分方面的差异。结果单因素和多因素预后分析结果均显示,年龄、SUVmax、IPI评分均为DLBCL患者的预后影响因素。相对危险度(relative risk,RR)分别为RR(>60岁/≤60岁)=12.56(95%CI:3.32~47.54),RR(SUVmax值>10/SUVmax值≤10)=3.11(95%CI:1.04~9.34),RR(>2分/≤2分)=5.67(95%CI:1.09~29.60)。免疫学标志物CD10、BCL-6、MUM-1的表达以及免疫学分型与患者预后差异无统计学意义(P>0.05)。SUVmax≤10组和SUVmax>10组在年龄、分期等各临床指标之间的差异无统计学意义(P>0.05)。结论治疗前^18F-FDG PET/CT显像的SUVmax值对DLBCL患者R-CHOP方案治疗后生存预测有一定临床指导意义。Objective To investigate the survival predictive value of the maximum standard uptake value(SUVmax)of^18F-fluorodeoxy glucose(^18F-FDG)in positron emission tomography/computed tomography(PET/CT)in diffuse large B cell lymphoma(DLBCL)patients before R-CHOP treatment.Methods The clinical data of 76 DLBCL patients who underwent PET/CT examination before R-CHOP treatment in our hospital from 2015 to 2019 were collected.The age,gender,^18F-FDG SUVmax value of PET/CT imaging,immunological markers and immune types of these DLBCL were analyzed using R-Studio software for prognosis by univariate and multivariate analyses.According to the^18F-FDG SUVmax value,the 76 patients were divided into the SUVmax≤10 group and the SUVmax>10 group.Chi-square test was used to compare the differences in the age,gender,clinical stage,B symptoms,LDH level,and international prognostic index(IPI)between the 2 groups.Results Both the univariate or multivariate analyses showed that age,^18F-FDG SUVmax and IPI score were all prognostic factors for prognosis in DLBCL patients,The relative risk(RR)was 12.56 for those>60 years old/≤60 years old(95%CI:3.32~47.54),3.11 for SUVmax>10/SUVmax≤10(95%CI:1.04~9.34),and 5.67 for IPI score>2/≤2(95%CI:1.09~29.60).No statistical relationship were found in the expression of immunological markers,CD10,BCL-6 and MUM-1 with the prognosis(P>0.05).There were no significant differences in age,clinical stage and other clinical indicators between the SUVmax≤10 group and the SUVmax>10 group(P>0.05).Conclusion The SUVmax value of^18F-FDG PET/CT imaging before treatment is of certain significance in the survival prediction for DLBCL patients after R-CHOP chemotherapy.

关 键 词：^18F-FDG PET/CT SUVMAX 弥漫大B细胞淋巴瘤 R-CHOP治疗 Kaplan-Meier评估 

分 类 号：R730.53[医药卫生—肿瘤] R733.4[医药卫生—临床医学]